This analysis performed signal identification for Zarxio (filgrastim-sndz) compared with Neupogen (filgrastim) by monitoring non-pregnancy and non-cancer outcomes among new users of Zarxio or Neupogen. This is a follow up to a previous analysis to add a propensity score model without calendar year.
The study period includes data from November 5, 2016 to December 9, 2022.
The analytic package associated with this analysis can be found externally in Sentinel's Git Repository located here. The Git Repository serves as Sentinel's version control tracking system for analytic packages and technical documentation.